Lyra Therapeutics, Inc. (LYRA)
NASDAQ: LYRA · Real-Time Price · USD
24.28
-1.05 (-4.15%)
At close: Jun 6, 2025, 4:00 PM
25.40
+1.12 (4.61%)
After-hours: Jun 6, 2025, 7:59 PM EDT
Lyra Therapeutics Employees
Lyra Therapeutics had 30 employees as of December 31, 2024. The number of employees decreased by 58 or -65.91% compared to the previous year.
Employees
30
Change (1Y)
-58
Growth (1Y)
-65.91%
Revenue / Employee
$39,500
Profits / Employee
-$2,651,000
Market Cap
32.18M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
LYRA News
- 6 days ago - Why Is Lyra Therapeutics Stock Surging Over 400% On Monday? - Benzinga
- 6 days ago - Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS) - GlobeNewsWire
- 4 weeks ago - Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025 - GlobeNewsWire
- 4 weeks ago - Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 months ago - Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 8 months ago - Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis - GlobeNewsWire
- 9 months ago - Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings - GlobeNewsWire